Breakthrough in Early Cancer Detection: Largest Proteomics Study Completed

Introduction: Unprecedented Study in Cancer Detection

Seer, Inc. recently announced the completion of the largest and most detailed proteomics study ever conducted. Utilizing the Seer Proteograph™ Product Suite and Thermo Fisher Scientific’s advanced mass spectrometers, this groundbreaking research focused on the early detection of cancer.

Scale and Depth of Research

The study involved an impressive cohort of 2,840 subjects across various types of cancer. Researchers were able to identify over 13,000 unique protein groups in plasma, with an average of more than 8,200 proteins detected per sample. This massive dataset was made possible through state-of-the-art technology, including Seer’s proprietary instruments and Thermo Fisher's Thermo Scientific™ Orbitrap™ Astral™ mass spectrometer.

PrognomiQ's Role and Methodology

PrognomiQ, a leader in multi-omics research, collected blood samples from 77 different clinical sites across the United States. These samples were then processed through Seer’s innovative Proteograph SP100 systems and XT assays. The resulting peptides were sent to the Seer Technology Access Center (STAC) for analysis. The study highlighted the exceptional depth and sensitivity of Seer’s proteomics technology.

Implications of Findings

The data gathered from this study offers unprecedented biological insights that can significantly advance the early detection of cancer. The comprehensive proteomic profiling conducted allows for the identification of biomarkers critical for early diagnosis.

Statements from Industry Leaders

The significance of this study was underscored by Bruce Wilcox, Chief Technology Officer of PrognomiQ, who emphasized its potential to transform cancer detection. John Lesica, President of Chromatography and Mass Spectrometry at Thermo Fisher, and Omid Farokhzad, CEO and Chair of Seer, also praised the collaborative effort and the resulting advancements in proteomics research.

Presentation at ASMS Conference

Detailed results of this study will be presented by Dr. Bruce Wilcox at the American Society of Mass Spectrometry (ASMS) Conference. This presentation will provide further insights into the groundbreaking findings and their implications for future cancer research.

About Seer

Seer is a pioneering life sciences company specializing in proteomics technology. Their Proteograph Product Suite is an innovative solution designed for deep, unbiased proteomic analysis. Seer’s technological advancements aim to provide transformative insights into the human proteome.

About PrognomiQ

PrognomiQ, founded in 2020, focuses on developing advanced testing solutions for cancer and other complex diseases. Using cutting-edge proteomics, metabolomics, and genomics technologies, the company is at the forefront of multi-omics research.

Future Outlook

The completion of this study marks a significant leap forward in cancer detection research. The collaboration between Seer and Thermo Fisher highlights the importance of combining advanced technologies to drive innovation in healthcare.